Oftalmol Zh.2015;2:55-61


Ability of medication correction by means neurotropic drugs for disorders in metabolical cycle of neurotoxic transmitter — glutamat in retina during experimental glaucoma 

V. Serduk 

Municipal Dnipropetrovsk regional ophthalmology clinic; Dnipropetrovsk (Ukraine)

The aim of this scientific work is to study the abilities of medical correction of violations in metabolic cycle of glutamine acid in the retina of 53 rabbits with experimental glaucoma using enzymatic analysis. 

Experimental animals were divided on 3 groups: intact (control group), research group with glaucoma, research group with glaucoma treated by neuroprotectors. Supervision was made at 3 weeks 1st term, 5–6 weeks 2nd term, 10 weeks 3rd term. We used Mema in dose 5 mg/kg per day, Neurodar 100 mg/kg per day everyday through all term of experiment. 

Results. Еhe concentration of glutamate in the retina of animals was increased to 14.90±0.75 mkmol/g (120.0 % of normal level 12.42±0.60 mkmol/g) at 1st term of glaucoma process development, 19.87±0.80 mkmol/g (160.0 %) and 21.76±0.70 mkmol/g (175.2 %) at 2nd and 3rd terms. 

Concentration of glutamate with usage of neuroprotectors was 14.28±0.62 mkmol/g (115.0 %) at 1st term, 16.17±0.74 mkmol/g (130.2 %) at 2nd term, 16.77±0.56 mkmol/g (135.0 %) at 3rd term. 

The positive effect of neuroprotective therapy was also admitted on activity of glutamine synthetase, glutamate oxidase and glutaminase enzyms. 

Key words: glaucoma, glutamate, glutamine, glutamine synthetase, glutamate oxidase, glutaminase, memantine, citicoline.


  1. Alekseev VN, Martynova EB, Samusenko IA. The role of apoptosis and metabolism of Muller cells in experimental glaucoma. Klinich. Oftalmol. 2005;5: 52–55. In Russian. 
  2. Alyabieva ZhYu. Vascular risk factors in the development of glaucoma with normal pressure. Klinich. Oftalmol. 2001;2(2):6–8. In Russian. 
  3. Bunin AYa. Metabolic factors of pathogenesis of primary open — angle glaucoma. Glaucoma: outcomes and prospects. Proceedings of scient. Pract/ conference. M.; 1999. 9–12. In Russian. 
  4. Volkov VV. Triple classification of open — angle glaucoma based on the concepts of its pathogenesis. Glaucoma. 2004;1:57–7. In Russian. 
  5. Naslyedov A. SPSS computer analysis of data in psychology and the social sciences. Spb.:Piter; 2005. 416 p. 
  6. Agar A, Li S. Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res. 2006;1086:191–200. 
    Crossref   Pubmed
  7. Benozzi J, Nahum LP, Campanelli JL. Effect of hyaluronic acid on intraocular pressure in rats. Invest. Ophthalmol. Vis. Sci. 2002;43:2196–200. 
  8. Bergmeyer HU. Methoden der enzymatischen Analyse. Berlin. 1986.2254–65. 
  9. Carter — Dawson L, Crawford ML, Harwerth RS. Vitreal glutamate concentration in monkeys with experimental glaucoma. 2002;43:2633–7. 
  10. Danbolt NC. Glutamate uptake. Prog. Neurobiol. 2001; 65:1–105. 
  11. Dreyer EB, Surakowski D, Schumer RA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 1996; 114:299–305. 
  12. Flammer J, Haefliger I. Vascular Dysregulation: A principal risk factor for glaucomatous damage? J. Glaucoma. 1999;8:212–9. 
  13. Gulati V, Agarwal H, Sihota R. Monitoring glaucoma in the developing world. Asian J. Ophthalmol. 2002;4(1); 3–8. 
  14. Guo L, Salt TE, Maass A. Assessment of neuroprotective effects of glutamate modulation on glaucoma related retinal ganglion cell apoptosis in vivo. Invest. Ophthalmol. Vis. Sci. 2006;47:626–33. 
    Crossref   Pubmed
  15. Harada T, Harada C, Nakamura K. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J. Clin. Invest. 2007; 117(7):1763–70. 
    Crossref   Pubmed
  16. Heijl A, Leske C. Reduction of intraocular pressure and glaucoma progression. Arch. Ophthalmol. 2002;120:1268–79. 
    Crossref   Pubmed
  17. Kusari J, Zhou S, Padillo E. Effect of mementhine on neuroretinal function and retinal vascular changes of streptozotocin — induced diabetic rats. Invest. Ophthalmol. Vis. Sci. 2007;48:5152–9. 
  18. Lagreze WA, Otto T, Feuerstein TJ. Neuroprotection in ischemia of the retina an animal model. Ophthalmologe. 1999;96(6):370–4. 
  19. Moreno MC, Sande P, Marcos HA. Effect of glaucoma on the retinal glutamate/glutamine cycle activity. FASEB J. 2005;19(9):1161–2. 
  20. Neufeld A. New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. J. Glaucoma. 1998;7(6):434–8. 
  21. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006;90:262–7. 
  22. Ritch R, Shields M, Krupin T. The Glaucomas. St. Luis: CV Mosby, 1996. 432 p. 
  23. Schroder A, Erb C. Einsatz von memanthine bei glaucoma fere absolutum. Klin. Monatsbl. Augenheilkd. 2002;219:533–6. 
  24. Yoles E, Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch. Ophthalmol. 1998;116:906–10.